sucrose

• Association of indexes of liver health with fructose or sucrose intake

  unclear

  the apparent association between indexes of liver health (ie, liver fat, hepatic de novo lipogenesis, alanine aminotransferase, AST, and γ-glutamyl transpeptase) and fructose or sucrose intake appear to be confounded by excessive energy intake

  PMID:25099546 · one of two readings recorded this

• Liver fat and AST concentrations

  increases

  We found a low level of evidence that a hypercaloric fructose diet (supplemented by pure fructose) increases liver fat and aspartate aminotransferase (AST) concentrations in healthy men compared with the consumption of a weight-maintenance diet

  PMID:25099546 · one of two readings recorded this

• Liver fat and liver enzymes

  no effect

  In addition, there was a low level of evidence that hypercaloric fructose and glucose diets have similar effects on liver fat and liver enzymes in healthy adults

  PMID:25099546 · one of two readings recorded this

• NAFLD

  unclear

  There was insufficient evidence to draw a conclusion for effects of HFCS or sucrose on NAFLD

  PMID:25099546 · one of two readings recorded this

• PIPP after heel lance

  decreases, n = 164

  PIPP 60 s after heel lance WMD -2.14 (95% CI -3.34 to -0.94; I(2) = 0% (no heterogeneity; 2 studies, n = 164)

  PMID:27420164 · one of two readings recorded this

• PIPP during intramuscular injection

  decreases, n = 232

  PIPP during intramuscular injection WMD -1.05 (95% CI -1.98 to -0.12; I(2) = 0% (2 groups in 1 study, n = 232)

  PMID:27420164 · one of two readings recorded this

• PIPP during venipuncture

  decreases, n = 213

  PIPP during venipuncture WMD -2.79 (95% CI -3.76 to -1.83; I(2) = 0% (no heterogeneity; 2 groups in 1 study, n = 213)

  PMID:27420164 · one of two readings recorded this

• bradycardia incidence

  no effect, n = 194

  bradycardia (RR, 0.73; 95% CI, 0.32–1.68)

  PMID:28178172 · one of two readings recorded this

• crying time

  decreases, n = 166

  S+NNS shortened the crying time of NICU newborns significantly (MD, −0.92; 95% CI, −1.39 to −0.44)

  PMID:28178172 · one of two readings recorded this

• desaturation incidence

  no effect, n = 194

  desaturations (RR, 0.73; 95% CI, 0.32–1.68)

  PMID:28178172 · one of two readings recorded this

• neonatal procedural pain score (PIPP, NFCS, N-PASS pooled mean difference), oral sucrose combined with non-nutritive sucking versus single measure (sucrose or NNS alone)

  decreases

  Not recorded as a finding: this platform holds no node for the endpoint

  The meta-analysis suggested that pain scores were significantly lower in the S+NNS group than in the control group.

  PMID:28178172 · one of two readings recorded this

• pain score

  decreases, n = 599

  with the mean difference being −0.52 (95% CI, −0.68 to −0.36)

  PMID:28178172 · one of two readings recorded this

• pain score

  no effect

  no statistic differences were detected with the mean difference being −0.67 (95% CI, −1.34 to 0.01)

  PMID:28178172 · one of two readings recorded this

• pain score

  decreases

  with the mean difference being −0.44 (95% CI, −0.61 to −0.26)

  PMID:28178172 · one of two readings recorded this

• pain scores in NICU newborns undergoing painful procedures, pooled mean difference

  decreases, MD, -0.52; 95% CI, -0.68 to -0.36

  Not recorded as a finding: the intervention held more than the compound

  The combination of oral sucrose and NNS is associated with reduced pain scores (mean difference [MD], -0.52; 95% confidence interval [CI], -0.68 to -0.36); shortened crying time (MD,-0.92; 95% CI, -1.39 to -0.44); but the 2 groups did not differ significantly in reducing bradycardia (MD, 0.73; 95% CI, 0.32-1.68), tachycardia (MD, 0.65; 95% CI, 0.38-1.10), or desaturations (MD, 0.73; 95% CI, 0.32-1.68).

  PMID:28178172 · one of two readings recorded this

• tachycardia incidence

  no effect, n = 154

  tachycardia (RR, 0.65; 95% CI, 0.38–1.10)

  PMID:28178172 · one of two readings recorded this

• incident type 2 diabetes

  no effect

  fructose (RR 1.04, 95% CI 0.84-1.29)

  PMID:28536126 · one of two readings recorded this

• incident type 2 diabetes

  decreases

  sucrose was associated with a decreased risk of type 2 diabetes (RR 0.89, 95% CI 0.80-0.98)

  PMID:28536126 · one of two readings recorded this

• incident type 2 diabetes

  no effect

  total sugars (RR 0.91, 95% confidence interval [CI] 0.76-1.09)

  PMID:28536126 · one of two readings recorded this

• incidence of adverse events

  decreases, p = 0.003

  The FCM group had a lower incidence of adverse events than the IS group (RR, 0.53; 95% CI, 0.35–0.80; I2 = 0%; P = 0.003)

  PMID:34011020 · one of two readings recorded this

• serum ferritin, after iron replacement

  increases, p = 0.0001, n = 709

  (MD, 24.41 ng/mL; 95% CI, 12.06–36.76; I2 = 75%; P = 0.0001)

  PMID:34011020 · one of two readings recorded this

• serum ferritin, after iron replacement

  increases, p = 0.008

  gynecologic patients: MD, 50.81 ng/mL; 95% CI, 13.17–88.45; P = 0.008

  PMID:34011020 · one of two readings recorded this

• serum ferritin, after iron replacement

  increases, p = 0.00001

  obstetric and gynecologic patients: MD, 11.94 ng/mL; 95% CI, 9.94–13.94; P < 0.00001

  PMID:34011020 · one of two readings recorded this

• serum ferritin, after iron replacement

  increases, p = 0.004

  obstetric patients: MD, 30.84 ng/mL; 95% CI, 10.10–51.59; I2 = 77%; P = 0.004

  PMID:34011020 · one of two readings recorded this

• serum ferritin, baseline

  no effect, p = 0.49, n = 709

  (MD, −0.42 ng/mL; 95% CI, −1.61 to 0.78; I2 = 45%; P = 0.49)

  PMID:34011020 · one of two readings recorded this

• serum hemoglobin, after iron replacement

  increases, p = 0.002, n = 910

  Following IV iron replacement, Hb levels were higher among patients who received IV FCM compared with those who received IV IS (MD, 0.67; 95% CI, 0.25–1.08; I2 = 92%; P = 0.002)

  PMID:34011020 · one of two readings recorded this

• serum hemoglobin, after iron replacement

  increases, p = 0.05

  gynecologic patients: MD, 0.50 g/dL; 95% CI, 0.00–0.99; P = 0.05

  PMID:34011020 · one of two readings recorded this

• serum hemoglobin, after iron replacement

  increases, p = 0.00001

  obstetric and gynecologic patients: MD, 1.66 g/dL; 95% CI, 1.47–1.85; P < 0.00001

  PMID:34011020 · one of two readings recorded this

• serum hemoglobin, after iron replacement

  increases, p = 0.00001

  obstetric patients: MD, 0.55 g/dL; 95% CI, 0.40–0.47; P < 0.00001

  PMID:34011020 · one of two readings recorded this

• serum hemoglobin, after iron replacement

  increases, p = 0.00001

  (MD, 0.53; 95% CI, 0.39–0.68; I2 = 0%; P < 0.00001)

  PMID:34011020 · one of two readings recorded this

• serum hemoglobin, baseline

  no effect, p = 0.48, n = 910

  Prior to iron replacement therapy, baseline Hb levels were similar in the FCM and IS groups (MD, 0.04 g/dL; 95% CI, −0.07 to 015; I2 = 0%; P = 0.48)

  PMID:34011020 · one of two readings recorded this

• heart rate

  no effect, p = 0.07

  Asmerom, 2013 | 170.5(14.7) | 44 | 164.9(14.6) | 45 | - | - | - | - | 0.07

  PMID:35522649 · one of two readings recorded this

• heart rate

  decreases, p = 0.0001

  Gao, 2018 | 138.6(7.9) | 22 | 154.2(9.0) | 22 | 151.6(9.6) | 21 | 156.8(7.2) | 21 | <0.0001

  PMID:35522649 · one of two readings recorded this

• heart rate

  decreases, p = 0.001

  Miller, 2009 | 135.64(7.71) | 14 | - | - | - | - | 150.64(7.53) | 14 | <0.001

  PMID:35522649 · one of two readings recorded this

• neonatal procedural pain score (PIPP, PIPP-R, NIPS, NFCS, N-PASS pooled SMD) during heel stick, ROP screening, venipuncture; oral sucrose combined with non-nutritive sucking versus NNS alone, sucrose alone, routine care, breast milk, glucose

  decreases, SMD = -2.66, 95%CI: -4.53, -0.78 (heel stick); SMD = -1.1, 95%CI: -2.03,-0.17 (ROP)

  Not recorded as a finding: this platform holds no node for the endpoint

  The results showed a better impact of NNS+sucrose in both heel stick (SMD = -2.66, 95%CI: -4.53, -0.78) and ROP group (SMD = -1.1, 95%CI: -2.03,-0.17).

  PMID:35522649 · one of two readings recorded this

• NIPS score

  decreases, n = 66

  Only one study enrolling 66 term newborns set glucose+NNS as the control group

  PMID:35522649 · one of two readings recorded this

• NIPS score

  decreases

  NIPS scores were significantly lower in the NNS+sucrose group (range 1–2 and median 0) compared with the NNS+glucose group (range 5–7 and median 6) during venipuncture

  PMID:35522649 · one of two readings recorded this

• oxygen saturation

  increases, p = 0.0001

  Asmerom, 2013 | 96.4(0.6) | 44 | 95.8(0.6) | 45 | - | - | - | - | <0.0001

  PMID:35522649 · one of two readings recorded this

• oxygen saturation

  increases, p = 0.05

  Gao, 2018 | 95.2(1.6) | 22 | 92.9(2.4) | 22 | 93.5(1.7) | 21 | 92.9(2.1) | 21 | <0.05

  PMID:35522649 · one of two readings recorded this

• oxygen saturation

  increases, p = 0.001

  Miller, 2009 | 97.69(2.41) | 14 | - | - | - | - | 94.30(3.74) | 14 | <0.001

  PMID:35522649 · one of two readings recorded this

• pain score during painful procedures in neonates (primary outcome), pooled SMD

  decreases, SMD = -1.39, 95% CI, -2.21,-0.57 (NNS+OS vs sucrose alone)

  Not recorded as a finding: the intervention held more than the compound

  The results demonstrated a significant reduction in pain score in the NNS+OS group compared with NNS alone (SMD = -1.69, 95%CI, -1.69,-0.65) or sucrose alone (SMD = -1.39, 95% CI, -2.21,-0.57) during the painful procedures.

  PMID:35522649 · one of two readings recorded this

• pain score during painful procedures in NICU infants, pooled SMD across studies

  decreases, SMD = -1.69, 95%CI, -1.69,-0.65 vs NNS alone; SMD = -1.39, 95% CI, -2.21,-0.57 vs sucrose alone

  Not recorded as a finding: the intervention held more than the compound

  The results demonstrated a significant reduction in pain score in the NNS+OS group compared with NNS alone (SMD = -1.69, 95%CI, -1.69,-0.65) or sucrose alone (SMD = -1.39, 95% CI, -2.21,-0.57) during the painful procedures.

  PMID:35522649 · one of two readings recorded this

• pain score

  n = 677

  A total of 11 studies with 677 participants explored the effect of OS combined with NNS compared with NNS alone during the painful procedures

  PMID:35522649 · one of two readings recorded this

• pain score

  decreases, n = 677

  Six studies involving 677 infants or newborns assessed the pain in the group applying sucrose alone

  PMID:35522649 · one of two readings recorded this

• pain score

  decreases

  In the recovery phase, the effect was also significant (MD = -3.48, 95%CI: -5.41, -1.54)

  PMID:35522649 · one of two readings recorded this

• pain score

  decreases, n = 268

  Five studies involving 268 participants were included in the analysis to compare the effect between the NNS+sucrose group and the routine care group

  PMID:35522649 · one of two readings recorded this

• pain score

  decreases, p = 0.001

  the reverse result (MD = -3.23, 95%CI: -4.56, -1.89, P<0.001) after removing Mitchell’s study in the sensitivity analysis

  PMID:35522649 · one of two readings recorded this

• pain score

  decreases

  In both heel-stick and ROP subgroups, a significant effect was observed under the random-effects model, with the standard mean difference being -1.59 (95%CI: -2.49, -0.68) and -1.05(95%CI: -1.56, -0.55), respectively

  PMID:35522649 · one of two readings recorded this

• pain score

  decreases

  In both heel-stick and ROP subgroups, a significant effect was observed under the random-effects model, with the standard mean difference being -1.59 (95%CI: -2.49, -0.68) and -1.05(95%CI: -1.56, -0.55), respectively

  PMID:35522649 · one of two readings recorded this

• pain score

  no effect, p = 0.16

  The analysis showed no effect in four studies involving term infants regardless of the type of procedures (p = 0.16) with SMD: -0.81 (95%CI: -1.94, 0.33)

  PMID:35522649 · one of two readings recorded this

• pain score

  no effect, p = 0.09

  No significant difference, however, was detected when studying the term subgroup (SMD = -1.30, 95%CI: -2.81, 0.22, P = 0.09)

  PMID:35522649 · one of two readings recorded this

• pain score

  decreases

  The results showed a better impact of NNS+sucrose in both heel stick (SMD = -2.66, 95%CI: -4.53, -0.78) and ROP group (SMD = -1.1, 95%CI: -2.03,-0.17)

  PMID:35522649 · one of two readings recorded this

• pain score

  decreases

  The results showed a better impact of NNS+sucrose in both heel stick (SMD = -2.66, 95%CI: -4.53, -0.78) and ROP group (SMD = -1.1, 95%CI: -2.03,-0.17)

  PMID:35522649 · one of two readings recorded this

• publication bias (Egger intercept)

  no effect, p = 0.3515

  The bias (intercept) was estimated -3.3 (95%CI -10.90, 4.30) with p value 0.3515 in the comparison between NNS+OS and NNS alone (11 studies)

  PMID:35522649 · one of two readings recorded this

• publication bias (Egger intercept)

  no effect, p = 0.117

  The estimates of bias were -5.60 (95%CI -13.40, 2.20) with p value 0.117 in the comparison between NNS+OS and OS alone (6 studies)

  PMID:35522649 · one of two readings recorded this

• adjudicated composite cardiovascular event excluding hypertension and hypotension

  no effect

  Running the same indirect analysis for the composite endpoint without hypotension or hypertension yielded an odds ratio of 0.54 (95% CI 0.28–1.06)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  no effect

  The random effects meta-analysis of the studies comparing FCM with IS yielded an odds ratio of 1.12 (95% CI 0.90–1.40)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  decreases

  Combining the results of the two meta-analyses using the Bucher et al. methodology yielded an odds ratio of 0.53 (95% CI 0.33–0.84) with FDI relative to FCM

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  decreases

  The random effects meta-analysis of the studies comparing FDI with IS yielded an odds ratio of 0.59 (95% confidence interval [CI]: 0.39–0.90)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  no effect

  CKD studies only | 0.58 (0.36–0.92) | 1.15 (0.91–1.45) | 0.50 (0.30–0.85)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  no effect

  Excluding 1VIT09031 | 0.59 (0.39–0.90) | 1.15 (0.91–1.45) | 0.51 (0.32–0.83)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  no effect

  Excluding CKD studies | 0.66 (0.23–1.92) | 0.78 (0.33–1.88) | 0.85 (0.22–3.34)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  no effect

  Excluding FERWONIDA | 0.58 (0.36–0.92) | 1.12 (0.90–1.40) | 0.52 (0.31–0.87)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  no effect

  Excluding FERWONNEPHRO | 0.66 (0.23–1.92) | 1.12 (0.90–1.40) | 0.59 (0.20–1.74)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  no effect

  Excluding REPAIR-IDA | 0.59 (0.39–0.90) | 0.78 (0.33–1.88) | 0.76 (0.29–1.99)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  no effect

  Fixed effects model | 0.59 (0.39–0.90) | 1.12 (0.90–1.40) | 0.53 (0.33–0.84)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  decreases

  CKD studies only | 0.58 (0.36–0.92) | 1.15 (0.91–1.45) | 0.50 (0.30–0.85)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  decreases

  Excluding 1VIT09031 | 0.59 (0.39–0.90) | 1.15 (0.91–1.45) | 0.51 (0.32–0.83)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  no effect

  Excluding CKD studies | 0.66 (0.23–1.92) | 0.78 (0.33–1.88) | 0.85 (0.22–3.34)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  decreases

  Excluding FERWONIDA | 0.58 (0.36–0.92) | 1.12 (0.90–1.40) | 0.52 (0.31–0.87)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  no effect

  Excluding FERWONNEPHRO | 0.66 (0.23–1.92) | 1.12 (0.90–1.40) | 0.59 (0.20–1.74)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  no effect

  Excluding REPAIR-IDA | 0.59 (0.39–0.90) | 0.78 (0.33–1.88) | 0.76 (0.29–1.99)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  decreases

  Fixed effects model | 0.59 (0.39–0.90) | 1.12 (0.90–1.40) | 0.53 (0.33–0.84)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  decreases

  CKD studies only | 0.58 (0.36–0.92) | 1.15 (0.91–1.45) | 0.50 (0.30–0.85)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  decreases

  Excluding 1VIT09031 | 0.59 (0.39–0.90) | 1.15 (0.91–1.45) | 0.51 (0.32–0.83)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  no effect

  Excluding CKD studies | 0.66 (0.23–1.92) | 0.78 (0.33–1.88) | 0.85 (0.22–3.34)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  decreases

  Excluding FERWONIDA | 0.58 (0.36–0.92) | 1.12 (0.90–1.40) | 0.52 (0.31–0.87)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  no effect

  Excluding FERWONNEPHRO | 0.66 (0.23–1.92) | 1.12 (0.90–1.40) | 0.59 (0.20–1.74)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  decreases

  Excluding REPAIR-IDA | 0.59 (0.39–0.90) | 0.78 (0.33–1.88) | 0.76 (0.29–1.99)

  PMID:35947351 · one of two readings recorded this

• adjudicated composite cardiovascular event

  decreases

  Fixed effects model | 0.59 (0.39–0.90) | 1.12 (0.90–1.40) | 0.53 (0.33–0.84)

  PMID:35947351 · one of two readings recorded this

• arrhythmia

  Arrhythmia | 0.10% | 0.00% | 0.70% | 1.60% | 0.00% | 0.00% | 1.40% | 1.00%

  PMID:35947351 · one of two readings recorded this

• baseline bodyweight

  bodyweight was 79.5 kg in the FCM group versus 84.7 kg in the IVSC group

  PMID:35947351 · one of two readings recorded this

• composite cardiovascular event

  Composite cardiovascular event | 0.80% | 1.20% | 4.10% | 6.90% | 4.00% | 5.00% | 13.70% | 12.10%

  PMID:35947351 · one of two readings recorded this

• composite CV endpoint events

  1VIT09031 | 1VIT09031 | NCT00982007 | FCM vs IS | Mixed | 253 | 10 | 220 | 11

  PMID:35947351 · one of two readings recorded this

• composite CV endpoint events

  Total | 1529 | 185 | 1505 | 167

  PMID:35947351 · one of two readings recorded this

• composite CV endpoint events

  Total | 2008 | 50 | 1000 | 41

  PMID:35947351 · one of two readings recorded this

• composite CV endpoint events

  FERWONIDA | IDA-03 | NCT02940886 | FDI vs IS | Mixed | 989 | 8 | 494 | 6

  PMID:35947351 · one of two readings recorded this

• composite CV endpoint events

  FERWONNEPHRO | CKD-04 | NCT02940860 | FDI vs IS | NDD CKD | 1019 | 42 | 506 | 35

  PMID:35947351 · one of two readings recorded this

• composite CV endpoint events

  REPAIR-IDA | 1VIT09030 | NCT00981045 | FCM vs IS | NDD CKD | 1276 | 175 | 1285 | 156

  PMID:35947351 · one of two readings recorded this

• composite excluding hypertension and hypotension

  Composite excluding hypertension and hypotension (%) | 0.20% | 0.00% | 2.40% | 4.30% | 0.80% | 0.50% | 5.50% | 5.40%

  PMID:35947351 · one of two readings recorded this

• death due to any cause

  Death due to any cause | 0.10% | 0.00% | 0.30% | 0.60% | 0.40% | 0.50% | 1.20% | 1.40%

  PMID:35947351 · one of two readings recorded this

• hospitalization for heart failure

  Hospitalization for heart failure | 0.00% | 0.00% | 1.20% | 2.60% | 0.00% | 0.00% | 3.00% | 2.60%

  PMID:35947351 · one of two readings recorded this

• hypertension event

  Hypertension | 0.20% | 0.80% | 1.70% | 2.00% | 2.80% | 2.70% | 7.40% | 4.40%

  PMID:35947351 · one of two readings recorded this

• hypotension event

  Hypotension | 0.30% | 0.40% | 0.20% | 0.40% | 0.40% | 2.30% | 1.80% | 3.20%

  PMID:35947351 · one of two readings recorded this

• non-fatal hospitalization for unstable angina

  Non-fatal hosp. for unstable angina | 0.00% | 0.00% | 0.00% | 0.20% | 0.00% | 0.00% | 0.90% | 0.20%

  PMID:35947351 · one of two readings recorded this

• non-fatal myocardial infarction

  Non-fatal myocardial infarction | 0.00% | 0.00% | 0.40% | 0.00% | 0.40% | 0.00% | 0.60% | 1.10%

  PMID:35947351 · one of two readings recorded this

• non-fatal stroke

  Non-fatal stroke | 0.00% | 0.00% | 0.30% | 0.20% | 0.00% | 0.00% | 0.20% | 0.20%

  PMID:35947351 · one of two readings recorded this

• time-dependency of cardiovascular event hazard (Schoenfeld residuals)

  no effect, p = 0.1936

  Schoenfeld residuals from the Cox proportional hazards regression model fit to the patient-level time-to-event data from FERWONNEPHRO showed no significant time-dependency (p = 0.1936)

  PMID:35947351 · one of two readings recorded this

• Hb change after excluding the Derman study (sensitivity analysis)

  no effect, p = 0.44

  the results suggested that iron sucrose and iron isomaltoside still resulted in comparable improvement in Hb for anemia (SMD=0; 95% CI=-0.16 to 0.16; P=0.44)

  PMID:38357109 · one of two readings recorded this

• Hb change

  no effect, p = 0.18

  iron isomaltoside showed similar change of Hb (SMD=0.14; 95% CI=-0.07 to 0.35; P=0.18)

  PMID:38357109 · one of two readings recorded this

• Hb responder

  no effect, p = 0.33

  iron isomaltoside demonstrated comparable Hb responder (SMD=1.41; 95% CI=0.71 to 2.81; P=0.33; Figure 3)

  PMID:38357109 · one of two readings recorded this

• incidence of adverse events

  no effect, p = 0.68

  The incidence of adverse events was similar between two groups (OR=1.11; 95% CI=0.68 to 1.82; P=0.68; Figure 7)

  PMID:38357109 · one of two readings recorded this

• serum ferritin at week 2

  increases, p = 0.02

  iron isomaltoside was associated with significantly improved serum-ferritin at week 2 than iron sucrose (SMD=204.79; 95% CI=38.23 to 371.35; P=0.02; Figure 6)

  PMID:38357109 · one of two readings recorded this

• serum ferritin

  no effect, p = 0.44

  serum ferritin (SMD=15.13; 95% CI=-23.45 to 53.71; P=0.44; Figure 4)

  PMID:38357109 · one of two readings recorded this

• transferrin saturation

  no effect, p = 0.3

  transferrin saturation (SMD=1.20; 95% CI=-1.08 to 3.47; P=0.30; Figure 5)

  PMID:38357109 · one of two readings recorded this

• APGAR score at five minutes, iv FCM observational studies

  The mean APGAR score at one minute and five minutes of life was 8.75±0.5 and 9±0.7, respectively

  PMID:38439125 · one of two readings recorded this

• APGAR score at one minute, iv FCM observational studies

  The mean APGAR score at one minute and five minutes of life was 8.75±0.5 and 9±0.7, respectively

  PMID:38439125 · one of two readings recorded this

• birth weight of newborns, iv FCM observational studies

  The mean birth weight of the newborns of the participants was 3394±163.36 g

  PMID:38439125 · one of two readings recorded this

• incidence of treatment-related adverse events

  decreases, p = 0.003

  The pooled odds ratio of incidence of adverse events was 0.5 (0.32, 0.79) with I2=0 per cent, P=0.003

  PMID:38439125 · one of two readings recorded this

• mean rise in Hb above three weeks, iv FCM observational studies

  increases

  The mean rise in Hb levels up to three weeks and above three weeks after iv FCM therapy was 1.98±0.42 g/dl and 2.28±0.97 g/dl, respectively

  PMID:38439125 · one of two readings recorded this

• mean rise in Hb level at 12 wk

  no effect, p = 0.09

  at 12 wk after iv iron therapy was 0.78 (−0.13, 1.69) g/dl (P=0.09, I2=98%)

  PMID:38439125 · one of two readings recorded this

• mean rise in Hb level up to four weeks

  increases, p = 0.0008

  The mean difference between the groups in mean rise in Hb levels up to four weeks after iv iron therapy was 0.57 (0.24, 0.9) g/dl (P=0.0008, I2=75%)

  PMID:38439125 · one of two readings recorded this

• mean rise in Hb up to three weeks, iv FCM observational studies

  increases

  The mean rise in Hb levels up to three weeks and above three weeks after iv FCM therapy was 1.98±0.42 g/dl and 2.28±0.97 g/dl, respectively

  PMID:38439125 · one of two readings recorded this

• mean rise in serum ferritin above three weeks, iv FCM observational studies

  increases

  The mean rise in serum ferritin levels up to three weeks and above three weeks after iv FCM therapy was 205.94±55.09 µg/L and 106.88±67.48 µg/L, respectively

  PMID:38439125 · one of two readings recorded this

• mean rise in serum ferritin up to three weeks, iv FCM observational studies

  increases

  The mean rise in serum ferritin levels up to three weeks and above three weeks after iv FCM therapy was 205.94±55.09 µg/L and 106.88±67.48 µg/L, respectively

  PMID:38439125 · one of two readings recorded this

• post-infusion Hb level at 12 wk

  increases, p = 0.004

  and at 12 wk after iv iron therapy was 0.92 (0.41, 1.43) g/dl (P=0.004, I2=85%)

  PMID:38439125 · one of two readings recorded this

• post-infusion Hb level at five to six weeks

  increases, p = 0.001

  at five to six weeks after iv iron therapy was 0.62 (0.48, 0.77) g/dl (P<0.001, I2=0%)

  PMID:38439125 · one of two readings recorded this

• post-infusion Hb level up to four weeks

  increases, p = 0.05

  The mean difference between the groups in post-infusion Hb levels up to four weeks after iv iron therapy was 0.38 (0.01, 0.75) g/dl (P=0.05, I2=82%)

  PMID:38439125 · one of two readings recorded this

• post-infusion serum ferritin at 12 wk

  no effect, p = 0.4

  at 12 wk after iv iron therapy was 17.61 (−23.6, 58.83) µg/L (P=0.4, I2=74%)

  PMID:38439125 · one of two readings recorded this

• post-infusion serum ferritin at five to six weeks

  no effect, p = 0.07

  at five to six weeks after iv iron therapy was 94.83 (−6.37, 196.04) µg/L (P=0.07, I2=88%)

  PMID:38439125 · one of two readings recorded this

• post-infusion serum ferritin up to four weeks

  increases, p = 0.0001

  The mean difference between the groups in post-infusion serum ferritin levels up to four weeks after iv iron therapy was 34.65 (29.66, 39.64) µg/L (P<0.0001, I2=0%)

  PMID:38439125 · one of two readings recorded this

• rise in serum ferritin at four to five weeks

  no effect, p = 0.17

  The mean difference in the rise in serum ferritin levels at four to five weeks after iv iron therapy was 106 (−44.35, 256.36) µg/L (P=0.17 and I2=90%)

  PMID:38439125 · one of two readings recorded this

• appetite for something savoury niAUC

  no effect, p = 0.188, n = 53

  there was no effect of S&SE (F (2, 104) = 1.70, p = 0.188)

  PMID:38553262 · one of two readings recorded this

• appetite for something sweet niAUC

  no effect, p = 0.133, n = 53

  there was no effect of formulation (F (2, 104) = 2.06, p = 0.133) on niAUC appetite for something sweet

  PMID:38553262 · one of two readings recorded this

• appetite for something sweet niAUC

  decreases, p = 0.006, n = 53

  There was an overall effect of ED (F (1, 156) = 7.82, p = 0.006) with lower appetite for sweet after ED1 compared to ED14 (mean Δ −843.03, SEM 301.39; 95% CI (−1438.36, −247.69))

  PMID:38553262 · one of two readings recorded this

• bloating niAUC

  increases, n = 53

  Neotame compared to sucrose on ED14 (mean Δ −960.06 mm∗min (units), SEM 332.79; 95% CI (−1615.63, −304.49)

  PMID:38553262 · one of two readings recorded this

• bloating niAUC

  increases, p = 0.004, n = 53

  there was a formulation by ED interaction (F (2, 156) = 5.72, p = 0.004) with higher sensations of bloating reported in the 3 h after StRebM compared to sucrose on ED14 (mean Δ −1017.92 mm∗min, SEM 332.79; 95% CI (−1673.49, −362.34)

  PMID:38553262 · one of two readings recorded this

• bloating niAUC

  decreases, n = 53

  There were also lower niAUC bloating values on ED14 compared to ED1 with the sucrose formulation (mean Δ −1017.52 mm∗min (units), SEM 318.58; 95% CI (−1646.82, −388.223))

  PMID:38553262 · one of two readings recorded this

• composite appetite score niAUC

  no effect, p = 0.583, n = 53

  the linear mixed model revealed there was no overall effect of S&SE formulation (F (2, 104) = 0.54, p = 0.583)

  PMID:38553262 · one of two readings recorded this

• composite appetite score niAUC

  decreases, p = 0.04, n = 53

  There was an overall effect of ED (F (1, 156) = 4.28, p = 0.040) with lower niAUC composite appetite scores on ED1 compared to ED14 (mean Δ −468.14 mm∗min, SEM 226.38; 95% CI (−915.31, −20.98))

  PMID:38553262 · one of two readings recorded this

• explicit liking for high relative to low fat foods (pre-post change)

  no effect, p = 0.056, n = 53

  there was no effect of S&SE formulation (F (2, 104) = 2.96, p = 0.056) on pre-post intake change in explicit liking for high relative to low fat foods

  PMID:38553262 · one of two readings recorded this

• ghrelin iAUC

  no effect, p = 0.648, n = 40

  there was no effect of formulation (F (2, 78) = 0.436, p = 0.648), ED (F (1, 99) = 0.002, p = 0.963) or formulation by ED interaction (F (2, 198) = 0.688, p = 0.505) on the iAUC ghrelin response

  PMID:38553262 · one of two readings recorded this

• GLP-1 iAUC

  no effect, p = 0.915, n = 40

  there was no effect of formulation (F (2, 81) = 0.089, p = 0.915), ED (F (1, 88) = 0.087, p = 0.769) or formulation by ED interaction (F (2, 87) = 0.383, p = 0.683) on the iAUC GLP-1 response

  PMID:38553262 · one of two readings recorded this

• glucose iAUC

  no effect, p = 0.074, n = 47

  Differences between sucrose and Neotame formulations ran in the same direction but did not reach the statistical threshold (mean Δ 0.069 mg/dL∗min, SEM 0.038; 95% CI (−0.007, 0.145); p = 0.074; d = −0.25)

  PMID:38553262 · one of two readings recorded this

• glucose iAUC

  decreases, p = 0.05, n = 47

  greater iAUC glucose values after the sucrose formulation compared to the StRebM (mean Δ 0.097 mg/dL∗min, SEM 0.037; 95% CI (0.023, 0.171); p < 0.05; d = −0.39)

  PMID:38553262 · one of two readings recorded this

• glucose iAUC

  no effect, p = 0.845, n = 47

  There was no effect of ED (F (1, 140) = 0.038, p = 0.845) with similar iAUC glucose values on ED1 and ED14

  PMID:38553262 · one of two readings recorded this

• implicit wanting for high fat relative to low fat foods (pre-post change)

  no effect, p = 0.153, n = 53

  there was no effect of formulation (F (2, 260) = 1.89, p = 0.153)

  PMID:38553262 · one of two readings recorded this

• insulin iAUC

  decreases, p = 0.001, n = 47

  Neotame (mean Δ 0.130 μIU/mL∗min, SEM 0.018; 95% CI (0.093, 0.166); p < 0.001; d = −0.71)

  PMID:38553262 · one of two readings recorded this

• insulin iAUC

  decreases, p = 0.001, n = 47

  greater iAUC insulin after the sucrose formulation compared to StRebM (mean Δ 0.169 μIU/mL∗min, SEM 0.018; 95% CI (0.133, 0.205); p < 0.001; d = −1.01)

  PMID:38553262 · one of two readings recorded this

• insulin iAUC

  no effect, p = 0.699, n = 47

  There was no overall effect of ED (F (1, 228) = 0.149, p = 0.699)

  PMID:38553262 · one of two readings recorded this

• nausea niAUC

  no effect, p = 0.25, n = 53

  there were no effects of formulation (F (2, 104) = 1.40, p = 0.250)

  PMID:38553262 · one of two readings recorded this

• pancreatic polypeptide iAUC

  no effect, p = 0.981, n = 40

  there was no effect of formulation (F (2, 183) = 0.019, p = 0.981)

  PMID:38553262 · one of two readings recorded this

• pancreatic polypeptide iAUC

  increases, p = 0.023, n = 40

  there was an overall effect of ED (F (1, 181) = 5.26, p = 0.023), with higher PP iAUC values on ED14 compared to ED1 (mean Δ 0.222 pg/mL∗min, SEM 0.097; 95% CI (0.031, 0.413))

  PMID:38553262 · one of two readings recorded this

• thirst niAUC

  increases, p = 0.015, n = 53

  There was a formulation by ED interaction on niAUC for thirst (F (2, 156) = 4.29, p = 0.015) with greater sensations of thirst after StRebM compared to sucrose on ED14 (mean Δ 1258.98 mm∗min, SEM 506.34; 95% CI (261.39, 2256.55))

  PMID:38553262 · one of two readings recorded this

• thirst niAUC

  increases, n = 53

  There was also greater niAUC thirst values on ED14 compared to ED1 in the Neotame formulation (mean Δ 1217.84 mm∗min, SEM 471.08; 95% CI (287.32, 2148.36))

  PMID:38553262 · one of two readings recorded this

• Blood glucose iAUC 0-120 min

  decreases, n = 85

  Similarly, there was a 41.13% (iAUC0-60min) and 20.26% (iAUC0-120min) glucose-lowering effect compared with the placebo in the carbohydrate-rich meal intake study

  PMID:39064681 · one of two readings recorded this

• Blood glucose iAUC 0-120 min

  decreases, n = 85

  The percentage reduction in the iAUC of blood glucose levels was 49.78% (iAUC0-60min) and 43.36% (iAUC0-120min), respectively, compared with the placebo in the sucrose drink intake study

  PMID:39064681 · one of two readings recorded this

• Blood glucose iAUC 0-60 min

  decreases, n = 85

  Similarly, there was a 41.13% (iAUC0-60min) and 20.26% (iAUC0-120min) glucose-lowering effect compared with the placebo in the carbohydrate-rich meal intake study

  PMID:39064681 · one of two readings recorded this

• Blood glucose iAUC 0-60 min

  decreases, n = 85

  The percentage reduction in the iAUC of blood glucose levels was 49.78% (iAUC0-60min) and 43.36% (iAUC0-120min), respectively, compared with the placebo in the sucrose drink intake study

  PMID:39064681 · one of two readings recorded this

• health-related quality of life, anxiety/depression domain, in venous leg ulcers

  increases

  reduce ulcer size and improve health-related quality of life in the domains of pain/discomfort and anxiety/depression for patients with difficult-to-heal noninfected venous leg ulcers (GRADE: Moderate)

  PMID:39070301 · one of two readings recorded this

• health-related quality of life, pain/discomfort domain, in venous leg ulcers

  increases

  reduce ulcer size and improve health-related quality of life in the domains of pain/discomfort and anxiety/depression for patients with difficult-to-heal noninfected venous leg ulcers (GRADE: Moderate)

  PMID:39070301 · one of two readings recorded this

• safety of dressings on noninfected wounds

  no effect

  The use of sucrose octasulfate-impregnated dressings with noninfected wounds is considered safe (GRADE: Moderate)

  PMID:39070301 · one of two readings recorded this

• ulcer size in venous leg ulcers

  decreases

  reduce ulcer size and improve health-related quality of life in the domains of pain/discomfort and anxiety/depression for patients with difficult-to-heal noninfected venous leg ulcers (GRADE: Moderate)

  PMID:39070301 · one of two readings recorded this

• wound closure in neuroischemic diabetic foot ulcers

  increases

  sucrose octasulfate-impregnated dressings result in faster wound closure in patients with difficult-to-heal noninfected neuroischemic diabetic foot ulcers (GRADE: Moderate)

  PMID:39070301 · one of two readings recorded this

• body mass index

  decreases, p = 0.005

  Weight and BMI were decreased in both groups (p < 0.001) but was most pronounced following SSRD (p = 0.006 and p = 0.005, respectively)

  PMID:39275354 · one of two readings recorded this

• baseline total IBS-SSS, responders vs non-responders

  no effect, p = 0.116

  month 6 (322 (258–366) vs. 282 (228–345); p = 0.116)

  PMID:39275354 · one of two readings recorded this

• baseline total IBS-SSS, responders vs non-responders

  no effect, p = 0.274

  week 2 (316 (240–352) vs. 255 (235–340); p = 0.274)

  PMID:39275354 · one of two readings recorded this

• baseline total IBS-SSS, responders vs non-responders

  no effect, p = 0.428

  week 4 (316 (240–352) vs. 262 (222–356); p = 0.428)

  PMID:39275354 · one of two readings recorded this

• BMI change from baseline at 6 months

  decreases, p = 0.009

  BMI (−0.25 (−0.85–0.03) vs. 0.07 (−0.35–0.77) kg/m2; p = 0.009)

  PMID:39275354 · one of two readings recorded this

• completion of 4-week intervention

  no effect, p = 1, n = 155

  Seventy-seven participants were randomized to SSRD of which 72 (93.5%) completed the 4-week intervention in comparison to 72 (92.3%) of the 78 participants randomized to low FODMAP (p = 1.00)

  PMID:39275354 · one of two readings recorded this

• completion of 6-month follow-up

  no effect, p = 0.499

  Fifty-three in the SSRD group (68.8%) and 49 (62.8%) in the low FODMAP group completed the 6-month follow-up (p = 0.499)

  PMID:39275354 · one of two readings recorded this

• correlation of decreased bloating with disaccharide intake

  p = 0.044

  In the SSRD group, there was a weak correlation between decreased bloating and disaccharide intake (rs = 0.245, p = 0.044)

  PMID:39275354 · one of two readings recorded this

• correlation of improvement in total IBS-SSS with total extraintestinal IBS-SSS

  p = 0.001

  There was a strong correlation between the improvements in total IBS-SSS and total extraintestinal IBS-SSS at both week 2, week 4 and month 6 (rs = 0.390, rs = 0.409, and rs = 0.439, respectively; p < 0.001 for all)

  PMID:39275354 · one of two readings recorded this

• correlation of improvement in total IBS-SSS with total extraintestinal IBS-SSS

  p = 0.001

  There was a strong correlation between the improvements in total IBS-SSS and total extraintestinal IBS-SSS at both week 2, week 4 and month 6 (rs = 0.390, rs = 0.409, and rs = 0.439, respectively; p < 0.001 for all)

  PMID:39275354 · one of two readings recorded this

• correlation of improvement in total IBS-SSS with total extraintestinal IBS-SSS

  p = 0.001

  There was a strong correlation between the improvements in total IBS-SSS and total extraintestinal IBS-SSS at both week 2, week 4 and month 6 (rs = 0.390, rs = 0.409, and rs = 0.439, respectively; p < 0.001 for all)

  PMID:39275354 · one of two readings recorded this

• fiber intake

  decreases, p = 0.001

  whereas fiber intake was reduced (p = 0.001)

  PMID:39275354 · one of two readings recorded this

• plan to continue modified diet vs return to normal diet

  p = 0.005

  A greater portion of participants in the SSRD group planned to continue with a modified SSRD (n = 28) instead of returning to normal diet (n = 11) (p = 0.005)

  PMID:39275354 · one of two readings recorded this

• preference for SSRD among those who tested both diets

  p = 0.032, n = 34

  22 (64.7%) preferred SSRD and 10 (29.4%) preferred low FODMAP (p = 0.032)

  PMID:39275354 · one of two readings recorded this

• protein intake

  increases, p = 0.002

  Protein intake was increased in the SSRD group (p = 0.002)

  PMID:39275354 · one of two readings recorded this

• responder rate (50% reduction of total IBS-SSS)

  decreases, p = 0.018

  There were fewer responders in those with a vegetarian diet when considering >100 points and 50% reduction of total IBS-SSS (p = 0.016 and p = 0.018, respectively)

  PMID:39275354 · one of two readings recorded this

• responder rate (ΔTotal IBS-SSS ≥ -100)

  week 2 (63.6% vs. 52.6%)

  PMID:39275354 · one of two readings recorded this

• responder rate (ΔTotal IBS-SSS ≥ -100)

  week 4 (67.5% vs. 65.4%)

  PMID:39275354 · one of two readings recorded this

• responder rate (ΔTotal IBS-SSS ≥ -100)

  month 6 (20.8% vs. 28.2%)

  PMID:39275354 · one of two readings recorded this

• responder rate (ΔTotal IBS-SSS ≥ -100)

  decreases, p = 0.016

  There were fewer responders in those with a vegetarian diet when considering >100 points and 50% reduction of total IBS-SSS (p = 0.016 and p = 0.018, respectively)

  PMID:39275354 · one of two readings recorded this

• responder rate (ΔTotal IBS-SSS ≥ -50)

  no effect, p = 0.661, n = 155

  at week 2 (79.2% vs. 73.1%; p = 0.661; 95% CI = −20–7.2)

  PMID:39275354 · one of two readings recorded this

• responder rate (ΔTotal IBS-SSS ≥ -50)

  no effect, p = 1, n = 155

  week 4 (79.2% vs. 78.2%; p = 1.000; 95% CI = −14–12)

  PMID:39275354 · one of two readings recorded this

• responder rate (ΔTotal IBS-SSS ≥ -50)

  no effect, p = 0.252

  At follow-up, there was no significant difference between the responder rates in the groups when calculated by Fisher’s exact test (36.4% vs. 42.3%; p = 0.252)

  PMID:39275354 · one of two readings recorded this

• sugar craving and saturation

  decreases

  Sugar craving was decreased, especially following SSRD, whereas the degree of saturation was unaffected

  PMID:39275354 · one of two readings recorded this

• weight change from baseline at 6 months

  decreases, p = 0.005

  weight (−0.7 (−2.5–0.1) vs. 0.2 (−0.7–2.2) kg; p = 0.005)

  PMID:39275354 · one of two readings recorded this

• weight

  decreases, p = 0.006

  Weight and BMI were decreased in both groups (p < 0.001) but was most pronounced following SSRD (p = 0.006 and p = 0.005, respectively)

  PMID:39275354 · one of two readings recorded this

• breathing rate across time points

  modulates, p = 0.001

  P value within the groups | < 0.0001† | 0.002† | 0.001†

  PMID:39465388 · one of two readings recorded this

• breathing rate across time points

  modulates, p = 0.0001

  P value within the groups | < 0.0001† | 0.002† | 0.001†

  PMID:39465388 · one of two readings recorded this

• breathing rate across time points

  modulates, p = 0.002

  P value within the groups | < 0.0001† | 0.002† | 0.001†

  PMID:39465388 · one of two readings recorded this

• breathing rate

  no effect, p = 0.645

  Breathing rate | Before blood sampling | 49.68 ± 3.18 | 49.54 ± 4.17 | 48.55 ± 2.50 | 0.645*

  PMID:39465388 · one of two readings recorded this

• breathing rate

  decreases, p = 0.0001

  During blood sampling | 52.82 ± 3.31 | 47.37 ± 4.65 | 51.27 ± 2.58 | < 0.0001*

  PMID:39465388 · one of two readings recorded this

• breathing rate

  decreases, p = 0.006

  Five minutes after blood sampling | 51.59 ± 4.18 | 46.72 ± 4.79 | 49.91 ± 3.55 | 0.006*

  PMID:39465388 · one of two readings recorded this

• heart rate

  no effect, p = 0.12

  Number of heartbeats | Before blood sampling | 165.32 ± 10.55 | 157.68 ± 11.08 | 158.45 ± 13.51 | 0.120*

  PMID:39465388 · one of two readings recorded this

• heart rate

  decreases, p = 0.0001

  During blood sampling | 169.91 ± 10.41 | 152.95 ± 12.05 | 160.45 ± 15.08 | < 0.0001*

  PMID:39465388 · one of two readings recorded this

• heart rate

  decreases, p = 0.0001

  Five minutes after blood sampling | 169.63 ± 10.41 | 151.95 ± 11.91 | 165.09 ± 12.83 | < 0.0001*

  PMID:39465388 · one of two readings recorded this

• oral sucrose vs control, physiological variables and pain during and after venipuncture

  modulates, p = 0.05

  a statistically significant difference was observed between the oral sucrose group and the control group (P < 0.05)

  PMID:39465388 · one of two readings recorded this

• oral sucrose vs kangaroo care, physiological variables and pain during and after venipuncture

  modulates, p = 0.0001

  during blood sampling, the average respiration rate, heart rate, oxygen saturation, and pain score in the oral sucrose group significantly differed from the kangaroo care group (P < 0.0001)

  PMID:39465388 · one of two readings recorded this

• oxygen saturation across time points

  modulates, p = 0.011

  P value within the groups | < 0.0001† | 0.004† | 0.011†

  PMID:39465388 · one of two readings recorded this

• oxygen saturation across time points

  modulates, p = 0.004

  P value within the groups | < 0.0001† | 0.004† | 0.011†

  PMID:39465388 · one of two readings recorded this

• oxygen saturation

  no effect, p = 0.133

  Oxygen saturation | Before blood sampling | 94.73 ± 2.05 | 95.73 ± 1.55 | 95.68 ± 2.19 | 0.133*

  PMID:39465388 · one of two readings recorded this

• oxygen saturation

  increases, p = 0.0001

  During blood sampling | 92.68 ± 2.14 | 96.41 ± 1.89 | 94.32 ± 2.76 | < 0.0001*

  PMID:39465388 · one of two readings recorded this

• oxygen saturation

  increases, p = 0.0001

  Five minutes after blood sampling | 92.00 ± 2.58 | 95.68 ± 1.70 | 94.50 ± 2.84 | < 0.0001*

  PMID:39465388 · one of two readings recorded this

• pain score across time points

  modulates, p = 0.006

  P value within the groups | < 0.0001† | 0.006† | < 0.0001†

  PMID:39465388 · one of two readings recorded this

• pain score

  no effect, p = 0.356

  Pain score | Before blood sampling | 2.55 ± 0.81 | 2.13 ± 0.83 | 2.59 ± 1.47 | 0.356*

  PMID:39465388 · one of two readings recorded this

• pain score

  decreases, p = 0.0001

  During blood sampling | 4.41 ± 0.66 | 2.59 ± 1.05 | 4.36 ± 1.09 | < 0.0001*

  PMID:39465388 · one of two readings recorded this

• pain score

  decreases, p = 0.0001

  Five minutes after blood sampling | 3.50 ± 1.05 | 1.68 ± 1.17 | 3.36 ± 1.67 | < 0.0001*

  PMID:39465388 · one of two readings recorded this

The whole record — 307 rows